NK Cells Treatment for COVID-19

Henan Medical University2 enrolled

Overview

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Novel Coronavirus Pneumonia

Interventions

NK CellsBIOLOGICAL

twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Male or female, aged at 18 years-65 years old * 2\. Pneumonia that is judged by chest radiograph or computed tomography * 3\. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain reaction(RT-PCR) from any diagnostic sampling source Exclusion Criteria: * 1\. Pregnancy or breastfeeding * 2\. Known HIV, HBV or HCV infection * 3\. Patients with malignant tumor, other serious systemic diseases and psychosis * 4\. Patients who are participating in other clinical trials * 5\. Inability to provide informed consent or to comply with test requirements

Locations (1)

The First Affiliated Hospital of Xinxiang Medical University

Xinxiang, Henan, China